Enveda valuation, funding and investors
Enveda works in drug discovery and development, based in Boulder, United States. Founded in 2019, it has about 381 employees.
- Last round
- Series E · $311M · Sep 2026
- Valuation at last round
- $2.00B
- Headcount
- 381 · up
- Grade
- A
- Founded
- 2019
Enveda valuation today
VCMC values Enveda at $2.0B today, with a range of $1.7B to $3.0B and a grade of A. The valuation starts from its last funding round, a Series E round in Sep 2026.
Valuation by date (101 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2019 | $12.4M | $4.52M – $34.1M | $15.3M (+24%) | before first round | – | unknown | D | 0% |
| 1 Feb 2019 | $12.7M | $4.64M – $35.0M | $15.5M (+21%) | before first round | – | unknown | D | 0% |
| 1 Mar 2019 | $13.1M | $4.75M – $35.9M | $15.6M (+19%) | before first round | – | unknown | D | 0% |
| 1 Apr 2019 | $13.4M | $4.88M – $36.8M | $15.7M (+17%) | before first round | – | unknown | D | 0% |
| 1 May 2019 | $13.8M | $5.01M – $37.8M | $15.9M (+15%) | before first round | – | unknown | D | 0% |
| 1 Jun 2019 | $14.1M | $5.15M – $38.8M | $16.0M (+13%) | before first round | – | unknown | D | 0% |
| 1 Jul 2019 | $14.5M | $5.28M – $39.8M | $16.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Aug 2019 | $14.7M | $5.33M – $40.2M | $16.3M (+11%) | before first round | – | unknown | D | 0% |
| 1 Sep 2019 | $14.8M | $5.38M – $40.6M | $16.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 Oct 2019 | $14.9M | $5.43M – $41.0M | $16.6M (+11%) | before first round | – | unknown | D | 0% |
| 1 Nov 2019 | $15.1M | $5.48M – $41.4M | $16.8M (+11%) | before first round | – | unknown | D | 0% |
| 1 Dec 2019 | $15.2M | $5.53M – $41.7M | $16.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jan 2020 | $15.3M | $5.58M – $42.1M | $17.1M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2020 | $15.5M | $5.63M – $42.5M | $17.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2020 | $15.6M | $5.68M – $42.9M | $17.4M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2020 | $15.7M | $5.73M – $43.3M | $17.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2020 | $15.9M | $5.78M – $43.6M | $17.7M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2020 | $16.0M | $5.84M – $44.0M | $17.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jul 2020 | $16.2M | $5.89M – $44.4M | $18.0M (+11%) | before first round | – | unknown | D | 0% |
| 1 Aug 2020 | $16.3M | $5.94M – $44.8M | $18.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Sep 2020 | $16.5M | $6.00M – $45.2M | $18.3M (+11%) | before first round | – | unknown | D | 0% |
| 1 Oct 2020 | $16.6M | $6.05M – $45.6M | $18.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 Nov 2020 | $16.8M | $6.11M – $46.1M | $18.7M (+11%) | before first round | – | unknown | D | 0% |
| 1 Dec 2020 | $16.9M | $6.16M – $46.5M | $18.8M (+11%) | before first round | – | unknown | D | 0% |
| 28 Dec 2020 | $32.7M | $21.5M – $99.4M | $65.3M (+100%) | after a round | – | unknown | C | 0% |
| 1 Jan 2021 | $33.0M | $21.5M – $99.4M | $65.3M (+98%) | after a round | – | unknown | C | 0% |
| 1 Feb 2021 | $35.0M | $21.5M – $99.4M | $65.3M (+87%) | after a round | – | unknown | C | 0% |
| 1 Mar 2021 | $36.9M | $21.5M – $99.4M | $65.3M (+77%) | after a round | – | unknown | C | 0% |
| 1 Apr 2021 | $39.1M | $21.5M – $99.4M | $65.3M (+67%) | after a round | – | unknown | C | 0% |
| 1 May 2021 | $41.4M | $21.5M – $99.4M | $65.3M (+58%) | after a round | – | unknown | C | 0% |
| 1 Jun 2021 | $43.9M | $21.5M – $99.4M | $65.3M (+49%) | after a round | – | unknown | C | 0% |
| 23 Jun 2021 | $153M | $108M – $391M | $276M (+80%) | after a round | – | unknown | C | 0% |
| 1 Jul 2021 | $155M | $108M – $391M | $276M (+77%) | after a round | – | unknown | C | 0% |
| 1 Aug 2021 | $163M | $108M – $391M | $276M (+69%) | after a round | – | unknown | C | 0% |
| 1 Sep 2021 | $172M | $108M – $391M | $276M (+61%) | after a round | – | unknown | C | 0% |
| 1 Oct 2021 | $180M | $108M – $391M | $276M (+53%) | after a round | – | unknown | C | 0% |
| 1 Nov 2021 | $189M | $108M – $391M | $276M (+46%) | after a round | – | unknown | C | 0% |
| 1 Dec 2021 | $199M | $108M – $391M | $276M (+39%) | after a round | – | unknown | C | 0% |
| 1 Jan 2022 | $209M | $108M – $391M | $276M (+32%) | after a round | – | unknown | C | 0% |
| 1 Feb 2022 | $220M | $108M – $391M | $276M (+26%) | after a round | 87 | unknown | C | 0% |
| 1 Mar 2022 | $230M | $108M – $391M | $276M (+20%) | after a round | 87 | unknown | C | 0% |
| 1 Apr 2022 | $242M | $108M – $391M | $276M (+14%) | after a round | 87 | unknown | C | 0% |
| 1 May 2022 | $253M | $108M – $391M | $276M (+9%) | after a round | 87 | unknown | C | 0% |
| 1 Jun 2022 | $266M | $108M – $391M | $276M (+3%) | after a round | 87 | unknown | C | 0% |
| 1 Jul 2022 | $276M | $106M – $391M | $276M (0%) | after a round | 87 | unknown | C | 0% |
| 1 Aug 2022 | $276M | $101M – $391M | $276M (0%) | after a round | 87 | unknown | C | 0% |
| 1 Sep 2022 | $276M | $96.1M – $391M | $276M (0%) | after a round | 87 | unknown | C | 0% |
| 1 Oct 2022 | $276M | $91.5M – $391M | $276M (0%) | after a round | 87 | unknown | C | 0% |
| 1 Nov 2022 | $276M | $86.9M – $391M | $276M (0%) | after a round | 87 | unknown | C | 0% |
| 1 Dec 2022 | $276M | $82.8M – $391M | $276M (0%) | after a round | 87 | unknown | C | 0% |
| 22 Dec 2022 | $422M | $297M – $897M | $632M (+50%) | after a round | 87 | unknown | B | 0% |
| 1 Jan 2023 | $427M | $297M – $897M | $632M (+48%) | after a round | 160 | growing | B | 0% |
| 1 Feb 2023 | $442M | $297M – $897M | $632M (+43%) | after a round | 160 | growing | B | 0% |
| 1 Mar 2023 | $456M | $297M – $897M | $632M (+39%) | after a round | 160 | growing | B | 0% |
| 1 Apr 2023 | $472M | $297M – $897M | $632M (+34%) | after a round | 160 | growing | B | 0% |
| 1 May 2023 | $487M | $297M – $897M | $632M (+30%) | after a round | 160 | growing | B | 0% |
| 1 Jun 2023 | $505M | $297M – $897M | $632M (+25%) | after a round | 160 | growing | B | 0% |
| 1 Jul 2023 | $522M | $297M – $897M | $632M (+21%) | after a round | 160 | growing | B | 0% |
| 1 Aug 2023 | $540M | $297M – $897M | $632M (+17%) | after a round | 160 | growing | B | 0% |
| 1 Sep 2023 | $559M | $297M – $897M | $632M (+13%) | after a round | 160 | unknown | B | 0% |
| 1 Oct 2023 | $605M | $315M – $953M | $671M (+11%) | after a round | 210 | up | B | 0% |
| 1 Nov 2023 | $630M | $315M – $953M | $671M (+7%) | after a round | 210 | up | B | 0% |
| 1 Dec 2023 | $654M | $315M – $953M | $671M (+3%) | after a round | 210 | up | B | 0% |
| 1 Jan 2024 | $671M | $315M – $953M | $671M (0%) | after a round | 210 | up | B | 0% |
| 1 Feb 2024 | $685M | $327M – $972M | $685M (0%) | after a round | 230 | growing | B | 0% |
| 1 Mar 2024 | $691M | $334M – $981M | $691M (0%) | after a round | 240 | growing | B | 0% |
| 1 Apr 2024 | $691M | $338M – $981M | $691M (0%) | after a round | 240 | growing | B | 0% |
| 1 May 2024 | $691M | $342M – $981M | $691M (0%) | after a round | 240 | growing | B | 0% |
| 1 Jun 2024 | $691M | $346M – $981M | $691M (0%) | after a round | 240 | growing | B | 0% |
| 1 Jul 2024 | $691M | $350M – $981M | $691M (0%) | after a round | 240 | growing | B | 0% |
| 1 Aug 2024 | $691M | $312M – $981M | $691M (0%) | after a round | 240 | up | B | 0% |
| 1 Sep 2024 | $691M | $310M – $981M | $691M (0%) | after a round | 240 | up | B | 0% |
| 1 Oct 2024 | $691M | $308M – $981M | $691M (0%) | after a round | 240 | up | B | 0% |
| 1 Nov 2024 | $697M | $309M – $990M | $697M (0%) | after a round | 250 | up | B | 0% |
| 22 Nov 2024 | $1.1B | $757M – $2.0B | $1.4B (+30%) | after a round | 250 | up | B | 0% |
| 1 Dec 2024 | $1.1B | $757M – $2.0B | $1.4B (+29%) | after a round | 250 | up | B | 0% |
| 1 Jan 2025 | $1.1B | $757M – $2.0B | $1.4B (+26%) | after a round | 250 | up | B | 0% |
| 1 Feb 2025 | $1.1B | $757M – $2.0B | $1.4B (+23%) | after a round | 250 | up | B | 0% |
| 1 Mar 2025 | $1.2B | $757M – $2.0B | $1.4B (+21%) | after a round | 250 | up | B | 0% |
| 1 Apr 2025 | $1.2B | $757M – $2.0B | $1.4B (+18%) | after a round | 250 | up | B | 0% |
| 1 May 2025 | $1.2B | $757M – $2.0B | $1.4B (+16%) | after a round | 250 | flat | B | 0% |
| 1 Jun 2025 | $1.2B | $757M – $2.0B | $1.4B (+13%) | after a round | 250 | flat | B | 0% |
| 1 Jul 2025 | $1.3B | $788M – $2.1B | $1.5B (+13%) | after a round | 299 | up | B | 0% |
| 1 Aug 2025 | $1.3B | $794M – $2.1B | $1.5B (+10%) | after a round | 310 | up | B | 0% |
| 1 Sep 2025 | $1.4B | $794M – $2.1B | $1.5B (+7%) | after a round | 310 | up | B | 0% |
| 5 Sep 2025 | $1.7B | $1.2B – $3.2B | $2.2B (+30%) | after a round | 310 | up | B | 0% |
| 1 Oct 2025 | $1.7B | $1.2B – $3.2B | $2.2B (+28%) | after a round | 310 | up | B | 0% |
| 1 Nov 2025 | $1.8B | $1.2B – $3.2B | $2.2B (+26%) | after a round | 324 | growing | B | 0% |
| 1 Dec 2025 | $1.8B | $1.2B – $3.2B | $2.2B (+23%) | after a round | 324 | growing | B | 0% |
| 1 Jan 2026 | $1.9B | $1.2B – $3.2B | $2.3B (+21%) | after a round | 332 | growing | B | 0% |
| 1 Feb 2026 | $1.9B | $1.2B – $3.2B | $2.3B (+18%) | after a round | 332 | growing | B | 0% |
| 1 Mar 2026 | $2.0B | $1.2B – $3.2B | $2.3B (+15%) | after a round | 332 | up | B | 0% |
| 1 Apr 2026 | $2.0B | $1.3B – $3.3B | $2.3B (+14%) | after a round | 377 | growing | B | 0% |
| 1 May 2026 | $2.1B | $1.3B – $3.3B | $2.3B (+11%) | after a round | 377 | growing | B | 0% |
| 1 Jun 2026 | $2.2B | $1.3B – $3.3B | $2.3B (+8%) | after a round | 389 | up | B | 0% |
| 1 Jul 2026 | $2.2B | $1.3B – $3.3B | $2.3B (+6%) | after a round | 389 | up | B | 0% |
| 1 Aug 2026 | $2.3B | $1.3B – $3.3B | $2.3B (+3%) | after a round | 389 | up | B | 0% |
| 1 Sep 2026 | $2.3B | $1.3B – $3.3B | $2.3B (0%) | after a round | 389 | up | B | 0% |
| 24 Sep 2026 | $2.0B | $1.7B – $3.0B | $2.6B (+30%) | after a round | 381 | up | A | 0% |
| 1 Oct 2026 | $2.0B | $1.7B – $3.0B | $2.6B (+29%) | after a round | 381 | up | A | 0% |
| 24 Oct 2026 | $2.0B | $1.7B – $3.0B | $2.6B (+27%) | after a round | 381 | up | A | 0% |
Key facts about Enveda
- Founded
- 2019
- Headquarters
- Boulder, United States
- Employees
- about 381 +23% in a year
- Total raised
- $715M
- Funding rounds
- 6
- Last round
- Series E Sep 2026
Enveda was founded in 2019 by Pieter Dorrestein and Viswa Colluru.
Enveda funding history
Enveda has 6 funding rounds on record, from Dec 2020 to Sep 2026, $715M in total. The latest disclosed valuation is $2.00B post-money (Series E, Sep 2026).
Series E 23 Sep 2026
Led by Catalio Capital Management; with Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital, T. Rowe Price Investment Management, Digitalis Ventures, Sovereign Wealth Fund, Alderline Group, Baillie Gifford, Premji Invest, FPV Ventures, True Ventures, Kinnevik, Dimension, Lifeforce Capital, Lux Capital.
Sources: finsmes.com, fiercebiotech.com, hlth.com and 2 more
$311M
$2.00B post-money
Series D 4 Sep 2025
Led by Premji Invest; with Baillie Gifford, Kinnevik, Lingotto Investment Management, Peakline Partners, FPV Ventures, Socium Ventures, Dimension, Level VC, KKR, IA Ventures, Lux Capital.
Sources: enveda.com, fiercebiotech.com, biopharmadive.com and 1 more
$150M
Series C 21 Nov 2024
Led by Kinnevik, FPV Ventures; with Baillie Gifford, Premji Invest, Lingotto Innovation, Lux Capital, Dimension, True Ventures, Cresset Partners, The Nature Conservancy, Henry R. Kravis.
Sources: enveda.com, fiercebiotech.com, siliconangle.com
$130M
Series B 21 Dec 2022
Led by Dimension; with FPV Ventures, JAZZ Venture Partners, Level VC, Amino Collective, Allen & Co, Possible Ventures, True Ventures, Lux Capital, Wireframe Ventures, Hummingbird VC, Two Sigma Ventures, Silicon Valley Bank.
Sources: businesswire.com, bizwest.com
$68M
Series A 22 Jun 2021
Led by Lux Capital; with Two Sigma Ventures, Hummingbird VC, Catalio Capital Management, Lifeforce Capital, True Ventures, Wireframe Ventures, Village Global, Recursion.
Sources: enveda.com, businesswire.com, coloradohometownweekly.com
$51M
$4.9M
Enveda investors
37 investors have backed Enveda; Lux Capital, True Ventures and Dimension and 4 more led at least one round.
- Lux Capital lead, 5 rounds
- Kinnevik lead, 3 rounds
- Premji Invest lead, 3 rounds
- Baillie Gifford 3 rounds
- Two Sigma Ventures 2 rounds
- Alderline Group
- Allen & Co
- Cresset Partners
- Durable Capital Partners
- Henry R. Kravis
- ICONIQ
- KKR
- Lightspeed
- Lingotto Innovation
- Lingotto Investment Management
- Recursion
- Silicon Valley Bank
- Sovereign Wealth Fund
- Surveyor Capital
- T. Rowe Price Investment Management
- The Nature Conservancy
What Enveda does
Enveda works in biotechnology, with 13 recorded offerings and customers in biotechnology, pharmaceuticals, agriculture and healthcare.
Enveda Therapeutics, Inc. is a biotechnology company engaged in drug discovery, with a focus on small molecules derived from natural sources. The company operates a platform that enables scientists to access and characterize a broad range of molecules from living organisms, supporting research in agriculture, nutrition, and manufacturing. Enveda also develops AI-powered tools for molecule prediction and property analysis, and is involved in sustainability and biodiversity conservation initiatives, including access- and benefit-sharing in accordance with international conventions.
Description from Veridion's company data.
Products and services
- Drug Discovery and Development
- Small Molecule Synthesis and Characterization
- Natural Product-Based Therapeutics Development
- AI-Driven Molecule Prediction and Characterization
- Chemical Library Management and Search
- Biodiversity Database Construction and Search
- Preclinical Therapeutic Candidate Evaluation
- Clinical Candidate Advancement Services
- Agricultural Biotechnology Solutions
- Nutritional Biotechnology Solutions
- Biotechnology Platform Development
- Sustainability and Biodiversity Consulting
- Access and Benefit-Sharing Services
Markets
- Biotechnology
- Pharmaceuticals
- Agriculture
- Healthcare
Technology
- Molecule Structure and Identity Prediction
- Molecule Properties Prediction
Business model
- Business-to-Business
- Manufacturing
- Enterprise
Industry codes (NAICS)
- 541714 Research and Development in Biotechnology (except Nanobiotechnology) 100% match
Questions about Enveda
What is Enveda worth?
Valuation $2.0B (range $1.7B to $3.0B), as of 24 Oct 2026. The last disclosed valuation was $2.00B (Series E, Sep 2026).
Has Enveda raised money?
Enveda has 6 funding rounds on record, from Dec 2020 to Sep 2026, $715M in total. The latest disclosed valuation is $2.00B post-money (Series E, Sep 2026).
Who has invested in Enveda?
Lux Capital, True Ventures, Dimension, FPV Ventures, Kinnevik and Premji Invest, and 31 more. Lead investors include Lux Capital, True Ventures, Dimension and FPV Ventures.
How many people work at Enveda?
About 381, up 23% over the last year. Headcount grew from 87 in Feb 2022 to 381 in Sep 2026.
What does Enveda do?
Enveda works in biotechnology, with 13 recorded offerings and customers in biotechnology, pharmaceuticals, agriculture and healthcare. Its main offerings are drug discovery and development, small molecule synthesis and characterization and natural product-based therapeutics development.
When was Enveda founded, and where is it based?
Enveda was founded in 2019 and is based in Boulder, United States. It has about 381 employees, up 23% over the last year.